<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04874623</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180354</org_study_id>
    <nct_id>NCT04874623</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibodies in Clostridium Difficile Infection</brief_title>
  <acronym>IgAClostridium</acronym>
  <official_title>Identification of IgA Monoclonal Antibodies Anti-Clostridium Difficile Surface Proteins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunoglobulin A (IgA), the major mucosal antibody, plays a key role in maintaining diversity&#xD;
      of the intestinal microbiota and eliminating intestinal pathogens. Dysbiosis is an important&#xD;
      risk factor for Clostridium difficile infection, which is the leading cause of nosocomial&#xD;
      diarrhea in industrialized countries. This study aims to develop IgA monoclonal antibodies&#xD;
      targeting C. difficile surface proteins.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immunoglobulin A (IgA), the major mucosal antibody, plays a key role in maintaining the&#xD;
      diversity of the intestinal microbiota and eliminating intestinal pathogens. They modulate&#xD;
      microbiota composition and also commensal bacteria homeostasis, thus promoting a symbiotic&#xD;
      relationship. These observations, derived from mouse studies, open promising therapeutic&#xD;
      perspectives: IgA could be used to restore or maintain a healthy microbiota in individuals&#xD;
      suffering from intestinal dysbiosis. Specific to a pathogen, IgA can also be considered as an&#xD;
      alternative to antibiotics by mimicking a physiological elimination.&#xD;
&#xD;
      Abnormalities in microbial diversity (i.e. dysbiosis) have been associated in humans with&#xD;
      various diseases such as Clostridium difficile infection, which is the leading cause of&#xD;
      nosocomial diarrhea in industrialized countries. The incidence of CDI has dramatically raised&#xD;
      since the early 2000s, with an increasing severity. Current treatments are limited to the&#xD;
      administration of antibiotics that unbalance the intestinal microbiota, a risk factor for&#xD;
      relapse. These frequent relapses contribute to the severity and chronicity of the infection.&#xD;
&#xD;
      This study aims to generate human IgA-type antibodies targeting C. difficile surface proteins&#xD;
      with neutralizing and/or protective activity. These antibodies will be selected against&#xD;
      surface proteins involved in the early stages of colonization. After injection or ingestion,&#xD;
      these IgA antibodies should reproduce physiological mucosal immunity, treat severe forms and&#xD;
      prevent the occurrence of C. difficile relapses while limiting deleterious effects on the&#xD;
      intestinal microbiota.&#xD;
&#xD;
      C. difficile-specific B cells will be selected from infected patients. After selection of the&#xD;
      most neutralizing IgA antibodies in vitro, these will be administered to C. difficile&#xD;
      infected mice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Generate C. difficile specific antibodies from circulating memory B lymphocytes of C. difficile patients.</measure>
    <time_frame>From the blood samples taken between Day 1 and Day 7 after the diagnostic of CDI</time_frame>
    <description>The presence of SlpA and Cwp84 specific memory B cells will be assessed from a single sample per patient. After separation of blood mononuclear cells, specific memory B cells will be selected using microfluidic drop technology. The variable VH and VL fragments of the immunoglobulins, which define the specificity of the antibodies, will be sequenced for each selected B cell. The corresponding antibodies will then be produced in a well-established cell line.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody affinity assessment</measure>
    <time_frame>From the blood samples taken between Day1 and Day7 after the diagnostic of CDI</time_frame>
    <description>The affinity of the antibodies will be evaluated by surface plasmon resonance (Biacore®).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing capacity evaluation affinity</measure>
    <time_frame>From the blood samples taken between Day1 and Day7 after the diagnostic of CDI</time_frame>
    <description>The neutralizing activity will be evaluated in vitro: the capacity of the antibodies to decrease the proliferation of the bacteria (in liquid culture), to decrease its mobility (solid culture), to inhibit biofilm formation and to inhibit its adhesion to the surface of intestinal epithelial cells (quantified using the Caco-213 line).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Clostridium Infection</condition>
  <arm_group>
    <arm_group_label>CDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of peripheral blood mononuclear cells</intervention_name>
    <description>Analysis of specific memory B cells in CDI patients</description>
    <arm_group_label>CDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patient, 18 years of age&#xD;
&#xD;
          -  diarrhea and/or abdominal pain.&#xD;
&#xD;
          -  Presence of C. difficile toxins in feces&#xD;
&#xD;
          -  Patient having dated and signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or nursing women&#xD;
&#xD;
          -  adult under guardianship&#xD;
&#xD;
          -  Ileus&#xD;
&#xD;
          -  Peritonitis&#xD;
&#xD;
          -  Pseudomembranous colitis&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Fever ≥ 38.5°C&#xD;
&#xD;
          -  Shivers&#xD;
&#xD;
          -  Respiratory failure&#xD;
&#xD;
          -  Leukocytosis &gt; 15x109/L&#xD;
&#xD;
          -  Serum creatinin &gt;50% reference values)&#xD;
&#xD;
          -  Serum lactate &gt; 5mM&#xD;
&#xD;
          -  Serum Albumine &lt; 30g/l&#xD;
&#xD;
          -  Other diarrhea cause&#xD;
&#xD;
          -  Humoral immunodeficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baptiste Hervier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baptiste Hervier, MD, PhD</last_name>
    <phone>0033142177622</phone>
    <email>baptiste.hervier@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine Sterlin, PharmD, PhD</last_name>
    <phone>0033142177518</phone>
    <email>delphine.sterlin@aphp.fr</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium difficile infection</keyword>
  <keyword>Therapeutic monoclonal antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

